Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
Van Poznak
Catherine H
CH
Hayes
Daniel F
DF
D018931:Antineoplastic Agents, Hormonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D020847:Estrogen Receptor Modulators / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015201:Meta-Analysis as Topic; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D011110:Polymorphism, Genetic; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013629:Tamoxifen / Q000493:pharmacokinetics / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D014408:Biomarkers, Tumor; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen